Given that insulin is a primary substrate of IDE, therapeutic enhancement of IDE activity could impair insulin clearance, worsening hyperinsulinemia and insulin resistance—especially in elderly or metabolically vulnerable individuals. Here, INS is linked to Hyperinsulinemia.